Literature DB >> 1685499

The use of flumazenil in the management of acute drug poisoning--a review.

A Weinbroum1, P Halpern, E Geller.   

Abstract

The popularity and widespread availability of benzodiazepines (BZD) has led to their frequent abuse in intentional drug poisoning. Although mortality from pure BZD overdose is usually small, in elderly, debilitated patients, or when BZD are combined with other CNS depressant drugs, morbidity increases significantly and outcome may be fatal. Drug overdose is therefore a medical emergency necessitating close observation and support of vital functions. Recently, the specific BZD antagonist flumazenil (Anexate) has become clinically available and much experience in its usefulness has accumulated. The present review summarizes a total of 30 studies and reports published to date, involving approximately 760 intoxicated patients. Flumazenil was evaluated both in prehospital use as well as in emergency rooms or in intensive care units. The age of patients ranged from 4-90 years and doses of flumazenil varied between 0.3-10 mg, approximately 1 mg being the most frequently used. All patients intoxicated with only BZD returned to full consciousness within minutes after the injection of flumazenil. When a mixture of BZD and other CNS depressants was abused, a range of effects was observed. This varied from no change to a return to full orientation, depending on the contribution of the BZD to the state of unconsciousness. Re-sedation occurred in about 65% of flumazenil treated patients, usually within 0.5-3 h after the first dose, the shorter interval being associated with mixed-drug poisoning. Repeated doses of the antagonist (0.2-2 mg), sometimes followed by continuous infusion (0.1-0.5 mg/h), were effective in maintaining patients fully oriented.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685499     DOI: 10.1007/bf01731152

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  29 in total

1.  Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol?

Authors:  U Klotz; G Ziegler; B Rosenkranz; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  The use of flumazenil in the treatment of 34 intoxicated patients.

Authors:  E Geller; D Niv; A Weinbrum; A Silbiger; P Halpern; P Sorkine
Journal:  Resuscitation       Date:  1988       Impact factor: 5.262

3.  Value of flumazenil in benzodiazepine self-poisoning.

Authors:  F Prischl; A Donner; G Grimm; R Smetana; K Hruby
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

4.  Reversal of chloral hydrate overdose with flumazenil.

Authors:  K L Donovan; D J Fisher
Journal:  BMJ       Date:  1989-05-06

5.  The use of anexate (Ro 15-1788) in acute self-poisoning with benzodiazepines alone or combined with other drugs--preliminary results.

Authors:  J M Rouzioux; F J Baud; C Bismuth; J Du Cailar; R Ducluzeau; A Durocher; F Flesch; G Bikpi-Benissan; A Jaeger; P Jean
Journal:  Resuscitation       Date:  1988       Impact factor: 5.262

6.  [Flumazenil: a useful antagonist in pediatrics].

Authors:  C Wood; D Oriot; I Robieux; D Devictor
Journal:  Arch Fr Pediatr       Date:  1988-02

7.  The use of flumazenil (Anexate, Ro 15-1788) in the management of drug overdose.

Authors:  B J Pollard; A P Masters; P Bunting
Journal:  Anaesthesia       Date:  1989-02       Impact factor: 6.955

8.  Specific treatment of benzodiazepine overdose.

Authors:  P Lheureux; R Askenasi
Journal:  Hum Toxicol       Date:  1988-03

9.  Flumazenil in the management of acute drug overdosage with benzodiazepines and other agents.

Authors:  G F O'Sullivan; D N Wade
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  5 in total

Review 1.  A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.

Authors:  A A Weinbroum; R Flaishon; P Sorkine; O Szold; V Rudick
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

2.  A comparison of intramuscular ketamine with high dose intramuscular midazolam with and without intranasal flumazenil in children before suturing.

Authors:  R McGlone; T Fleet; S Durham; S Hollis
Journal:  Emerg Med J       Date:  2001-01       Impact factor: 2.740

Review 3.  [Diagnosis, differential diagnosis and therapy of substance use disorders in general hospital (general section)].

Authors:  Anton Schmick; Josef Jenewein; Sönke Böttger
Journal:  Neuropsychiatr       Date:  2018-01-11

4.  Lorazepam-induced effects on silent period and corticomotor excitability.

Authors:  V K Kimiskidis; S Papagiannopoulos; D A Kazis; K Sotirakoglou; G Vasiliadis; F Zara; A Kazis; K R Mills
Journal:  Exp Brain Res       Date:  2006-03-09       Impact factor: 1.972

5.  Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature.

Authors:  José As Crippa; Guilherme N Derenusson; Marcos Hn Chagas; Zerrin Atakan; Rocio Martín-Santos; Antonio W Zuardi; Jaime Ec Hallak
Journal:  Harm Reduct J       Date:  2012-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.